What is new for MDS with del(5q)?

During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo,...

What are novel strategies to treat low-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Uwe...

Is there a place for immunotherapy in MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Shahram Kordasti,...

What are novel strategies to treat higher-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Mikkael...

Oral formulations of cedazuridine and decitabine for patients with MDS

Hypomethylating agents (HMAs), such as azacitidine and decitabine, are the main treatment options for myelodysplastic syndromes...

CA-4948, an IRAK4 inhibitor, attained orphan drug designation by the FDA for the treatment of relapsed/refractory MDS and AML

CA-4948 is a first-in-class, small-molecule inhibitor of interleukin-1...

DRSS: A new disease risk stratification system for hematologic malignancies

The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is largely dependent upon disease type and...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

How should molecular profiling be used to guide MDS therapy?

During the Acute Leukemia Forum (ALF) 2021, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, How should molecular...

Germline mutations in patients with hematologic malignancies

Germline mutations in patients with neoplasms are more common than expected and have been found not only in children but also adults with...

Editorial theme | Immune dysregulation and genetic mutations associated with MDS pathogenesis

The pathogenesis of myelodysplastic syndromes (MDS) is heterogeneous, involving inflammation, cytokines,...

Eprenetapopt with azacitidine for TP53-mutant MDS/AML: Results from two ongoing clinical trials

Patients with TP53-mutant myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience...